Precision medicine tool for informing the treatment of colon cancer in minutes

该项目旨在提高结肠癌诊断的准确性，降低成本和周转时间。目前，癌症诊断需要在病理学家确诊癌症后进行几次筛选分子测试。随着结肠癌发病率的增加和劳动力的老龄化（60.7%的病理学家年龄>55岁）以及covid19造成的严重积压，需要能够以具有成本效益和时间效益的方式缓解工作量压力的解决方案。Panakeia正在开发一种改变游戏规则的方法，用于直接从活检图像进行生物标志物检测，从而实现更快，更便宜，更准确的诊断和治疗决策，而无需湿实验室测试。在成功的初步概念验证（Proof of Concept，简称CET）研究的基础上，该项目在准确性和缩短的时间框架方面展示了非常有希望的结果，该项目为期18个月，旨在完善和验证该技术，以达到临床使用可接受的标准。

_This project aims to improve accuracy, reduce costs and turnaround times for the diagnosis of colon cancer. Currently, cancer diagnoses require several screening molecular tests subsequent to the confirmatory diagnosis of cancer by a pathologist.__With increasing colon cancer incidence and an ageing workforce (60.7% of pathologists being \>55 years of age) and severe backlogs due to covid19, there is a need for solutions capable of relieving workload pressures in a cost- and time-effective way.__Panakeia is developing a game-changing method for biomarker testing directly from biopsy images which enables faster, cheaper, more accurate diagnosis and treatment decision-making without needing wet-lab tests. Building on a successful initial Proof of Concept (PoC) study demonstrating very promising results in terms of accuracy and reduced timeframes, this 18-month project aims to refine and validate this technology to reach a standard acceptable for clinical use._